Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/2/2018
Start Date:January 26, 2010
End Date:January 31, 2020
Contact:Christopher King, MD
Phone:310-825-9771

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This is an observational study in which a questionnaire is used to obtain quality of life
data after patients undergo a hypo-fractionated course of stereotactic body radiotherapy
(SBRT) for the treatment of their prostate cancer. The SBRT itself is considered standard of
care for these patients and as such, is not an official component of the study.


Inclusion Criteria:

- Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level
<10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores
are involved).

- The ability to understand and willingness to sign a written informed consent are
necessary.

Exclusion Criteria:

- Patients with tumor parameters that fall outside of the inclusion criteria.

- Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of disseminated
disease.

- Patients who have had any form of prior prostate treatment (surgery, radiotherapy,
cryotherapy, high intensity focused ultrasound, TURP).

- A prior course of hormone therapy (androgen deprivation) of greater than 3 months
duration.

- The use of other concurrent investigational agents.

- There are no exclusions due to co-morbid disease or illnesses except for patients with
severe inflammatory bowel disease.

- No life expectancy restrictions will apply.

- Performance status will not be considered.
We found this trial at
1
site
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California 90095
Phone: 310-825-9771
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials